Complete Bibliography

Visit PubMed to view Dr. Jim Boonyaratanakornkit's complete publications list.

Selected Publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018

2024

Boonyaratanakornkit J, Wang Q, Nader A, Kimball L, Stevens-Ayers T, Levkova M, Blazevic R, Nguyen J, Wright J, Castor J, Greninger AL, Ford E, Mielcarek M, Fordred S, Han J, Boeckh M, Waghmare A: The Effect of Gastrointestinal Graft-Versus-Host Disease and Diarrhea on the Pharmacokinetic Profile of Sotrovimab in Hematopoietic Stem Cell Transplant Recipients. J Infect Dis. 2024 DOI: 10.1093/jiae236 

• Monoclonal antibodies provide an alternative or supplement to vaccination to protect against infectious diseases in vulnerable populations, but the pharmacokinetics of these antibodies is understudied in these populations.
• During the COVID-19 pandemic, we evaluated the pharmacokinetics of the long-acting monoclonal antibody sotrovimab targeting SARS-CoV-2 in a cohort of hematopoietic stem cell transplant recipients (the COVIDMAB clinical trial).
• Sotrovimab levels and exposure was significantly reduced in transplant recipients, particularly those who underwent allogeneic transplant, developed graft-versus-host disease, and developed diarrhea.
• These findings have implications for dose selection and duration of efficacy with potentially other monoclonal antibodies in vulnerable patient populations.

2023

Cabán M, Rodarte J, Bibby M, Gray MD, Taylor JJ, Pancera M, Boonyaratanakornkit J. Cross-protective antibodies against common endemic respiratory viruses. Nature Comm. 2023 Feb. DOI: 10.1038/s41467-023-36459-3.

• We leveraged a high-throughput screening strategy to identify two potent human antibodies, with one capable of neutralizing human parainfluenza virus types 1 and 3, and another capable of neutralizing respiratory syncytial virus and human metapneumovirus.  These antibodies represent promising candidates that could protect against a broad array of respiratory viral infections in highly vulnerable patient populations.
• Check out “Antibody cross-reactivity is metal” on This Week in Virology (TWiV), episode 989, for a video and podcast discussion of our findings by some of the OGs in virology (minute 31-64). https://www.youtube.com/watch?v=9MUJqoboliw

2022

Boonyaratanakornkit J, Boeckh M, Waghmare A. (2022) Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections. Curr Opin Infect Dis.

• This review article provides an overview of monoclonal antibodies in clinical use against respiratory viruses, highlights factors that modulate clinical efficacy, and provides a perspective on future innovations in the field.

2021

Boonyaratanakornkit J, Sholukh AM, Gray M, Bossard EL, Ford ES, Corbett KS, Corey L, and Taylor JJ. (2021) Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43. Viruses. (PMID 34696505)

• We developed and tested the performance of two readily accessible assays involving live virus for measuring antibody neutralization of human coronavirus OC43. We also describe the isolation of a OC43 neutralizing human monoclonal antibody. The assays described in this work could prove useful for studying humoral responses to OC43 and potentially for testing future vaccine or monoclonal antibody candidates.    

Boonyaratanakornkit J, Singh S, Weidle C, Bakthavatsalam R, Perkins J, Stewart-Jones GBE, Kwong PD, McGuire AT, Pancera M, Taylor JJ. (2021) Protective antibodies against human parainfluenza virus type 3 infection. mAbs. (PMID 33876699)

• We identified novel monoclonal antibodies to prevent and treat human parainfluenza virus type III. By leveraging a high-throughput screening strategy, we isolated several potent human antibodies and demonstrated the efficacy of one of these as both prophylaxis and therapy in an in vivo challenge model.

2020

Boonyaratanakornkit J, Morishima C, Selke S, Zamora D, McGuffin S, Shapiro AE, Campbell VL, McClurkan CL, Jing L, Gross R, Liang J, Postnikova E, Mazur S, Chaudhary A, Das MK, Fink SL, Bryan A, Greninger AL, Jerome KR, Holbrook MR, Gernsheimer TB, Wener MH, Wald A, Koelle DM. (2020) Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2 after COVID-19. J. Clin. Invest. (PMID 33052361)

• We found cutoffs for ELISA assays that were highly predictive of neutralizing Ab titers to SARS-CoV-2. We found that persons with more severe disease, increased age, and male sex had higher neutralizing antibody titers. We estimated the half-life of neutralizing antibody titers. We also found that a small subset of COVID-19 survivors were persistently seronegative. Taken together, we found that the immune response to SARS-CoV-2 was heterogeneous but that fast, accessible predictors of neutralizing antibody titers were readily available.

Boonyaratanakornkit J, Vivek M, Xie H, Pergam SA, Cheng GS, Mielcarek M, Hill JA, Jerome KR, Limaye AP, Leisenring W, Boeckh MJ, Waghmare A. (2019) Predictive Value of Respiratory Viral Detection in the Upper Respiratory Tract for Infection of the Lower Respiratory Tract with Hematopoietic Stem Cell Transplantation. J. Infect. Dis. (PMID 31541573)

• We examined the relationship between respiratory viruses found in the upper versus lower respiratory tract in hematopoietic stem cell transplant patients. We found high rates of discordance between the upper and lower tracts for several common respiratory viruses. The risk for lower tract infection was increased in patients with positive testing in the upper tract and in CMV seropositive recipients.  Our findings reinforce the importance of early lower tract testing in the management of respiratory viral infections in transplant candidates and recipients.

2019

Boonyaratanakornkit J, Taylor J. (2019) Techniques to Study Antigen-specific B cell Responses. Front. Immunol. (PMC6667631)

• This review summarizes established techniques and discusses new and emerging technologies for probing the B cell response in vitro and in vivo. We also present our approach to identify rare antigen-specific B cells using magnetic enrichment followed by flow cytometry. 

Boonyaratanakornkit J, Ekici S, Magaret A, Gustafson K, Scott E, Haglund M, Kuypers J, Pergamit R, Lynch J, Chu HY. (2019) Respiratory syncytial virus infection in the homeless population. Emerg Infect Dis. 25(7):1408-1411 (PMC6590761)

• This study examined the burden of RSV in the homeless population.  We found significant differences in risk factors, clinical course, and outcomes of adults hospitalized with RSV compared to influenza. In addition, patients with RSV were more likely to require ICU admission, receive antibiotics, and be readmitted. We identified the homeless as a previously unrecognized population at increased risk for poor outcomes after infection with RSV.  Public health strategies and a future RSV vaccine could significantly benefit this traditionally under-served population.  

2018

Boonyaratanakornkit J, Englund JA, Magaret AS, Bu, Y, Tielsch JM, Khatry SK, Katz J, Kuypers J, Shrestha L, LeClerq SC, Steinhoff MC, Chu HY. (2018) Primary and repeated respiratory viral infections among infants in rural Nepal. J Pediatric Infect Dis Soc. (PMID 30423150)

• This study examined the burden of primary and repeated respiratory viral infections in a birth cohort of infants from rural south Asia.  We found that infants frequently had a second infection with the same virus in the first six months of life, and that the second infection could be as severe as the first. The number of other children at home, male sex, and maternal education had a significant impact on risk of respiratory viral infection.  Our findings reinforce the importance of developing vaccines against multiple respiratory viruses and public health interventions to protect this vulnerable population, particularly in low-resource countries.